Dialysis, Plasma Bank, Serum Bank
Conditions
Brief summary
To be able to evaluate the predictive value of glycosylated ferritin as a predictive marker of hepatic iron stock in dialysis patients, we need to validate these results with a cohort of healthy volunteers.
Detailed description
This biological collection will include a sample of 2 dry tubes and 2 EDTA tubes. A haematological assessment (CBC, platelets, reticulocytes, Chr (hemoglobin content of reticulocytes), TP-INR, AST, ALT, GGT), measurement of biological markers of iron metabolism (ferritin, serum iron, CRP, transferrin, soluble receptors transferrin, transferrin saturation coefficient) as well as a creatinine assay to validate the normality of renal function in healthy volunteers (GFR established from the MDRD formula), a complete ionogram and a phosphocalcic balance being given the interactions in the dialysis patient (but also in normal subjects) between iron metabolism and phosphocalcic metabolism (calcemia, phosphoremia, PTH, 25OHD3, 1,25OH2D3) will be performed. We will also study the links between iron overload in dialysis patients and the modulation of the synthesis of parathyroid hormone (intact PTH), FGF23, alpha Klotho and sclerostin.
Interventions
BIOLOGICALBlood sample
Blood test (10 tubes of 5mL) : \- 6 tubes for : complete blood count, platelets, reticulocyte count, TP-INR, AST, ALT, GGT ferritin, serum iron, CRP, transferrin, soluble transferrin receptors, transferrin saturation coefficient enzymatic creatinine, MDRD, ionogram calcemia, phosphoremia, PTH, 25 (OH) D3, 1.25 (OH) 2D3. 2 dry tubes 2 tube EDTA
Sponsors
European Clinical Trial Experts Network
Ramsay Générale de Santé
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* Informed consent * Age over 18 years old * Healthy volunteers * Having given their informed consent in writing * Absence of current pathology * No current treatment (except contraception)
Exclusion criteria
* Refusal of consent or absence of signature * Minor, subject protected by law, (guardianship or curatorship, administrative protection measure) * Pregnant woman, parturient * Subject suffering from a condition liable to modify his blood parameters
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of participant with a serum and plasma bank creation | one day | it is only a serum and plasma bank constitution |
Countries
France
Outcome results
None listed